Fact-checked by Grok 2 weeks ago

Retinal migraine

Retinal migraine is a rare subtype of characterized by recurrent episodes of transient visual disturbances, including scotomas, scintillations, or temporary blindness in one eye, lasting 5 to 60 minutes and often followed by a typical within one hour. Unlike typical with aura, which involves binocular visual phenomena originating from the , retinal migraine is believed to involve the or , leading to unilateral symptoms. This condition is defined by the (ICHD-3) as fully reversible monocular visual symptoms accompanied by migraine headache, with at least two attacks required for diagnosis, and exclusion of other ocular or neurological disorders. It typically begins in the second decade of life, peaks in the fourth, and is more common in females, aligning with the broader of migraines that affect approximately 18% of women and 6.5% of men. The exact prevalence of retinal migraine is unknown due to its rarity and frequent misdiagnosis as other conditions like transient ischemic attacks.

Symptoms

The hallmark visual symptoms include scotomas (blind spots), flickering or zigzag lights, , or complete temporary vision loss in the affected eye, which resolves spontaneously without permanent damage in most cases. These episodes may occur with or without , but when present, the is often throbbing, unilateral (on the same side as the visual disturbance), and associated with , , or sensitivity to light and sound. Symptoms can be triggered by factors such as , high , , , hormonal contraceptives, low blood sugar, or exercise.

Causes and Pathophysiology

The underlying mechanism is thought to involve or reduced blood flow in the retinal or ciliary arteries, potentially leading to ischemia, as evidenced by showing delayed retinal filling during attacks. A is common, with about 50% of individuals having a family history of s, though the precise cause remains unclear and may overlap with broader , including neuronal spreading depression. Recent studies using optical coherence tomography (OCTA) have identified subtle vascular changes in the of patients, suggesting potential biomarkers for further research. Comorbidities such as , , or can increase risk.

Diagnosis

Diagnosis is clinical and primarily a process of exclusion, relying on patient history of recurrent episodes under age 50 without vascular risk factors, alongside normal eye examinations between attacks. Urgent evaluation by an ophthalmologist or neurologist is essential to rule out serious differentials like , , disease, , or , which may require imaging such as MRI or funduscopy. Any first-time or persistent visual symptoms warrant immediate medical attention to prevent misdiagnosis.

Treatment and Management

There are no specific FDA-approved treatments for retinal migraine, but management focuses on trigger avoidance through lifestyle modifications, such as quitting , maintaining , and tracking episodes in a . For acute attacks, over-the-counter pain relievers like ibuprofen or may help with , while preventive options for frequent episodes include (e.g., verapamil or ) or low-dose aspirin to improve blood flow. and ergotamines are generally avoided due to their vasoconstrictive effects, which could worsen retinal ischemia. In severe cases, referral to a neurologist for medications like topiramate or amitriptyline may be considered.

Prognosis

Retinal migraine is generally benign with full recovery of after each , though rare complications like permanent retinal damage or can occur if underlying vascular issues are present. Long-term outlook is favorable with proper , but ongoing using advanced like aims to refine understanding and treatment.

Overview

Definition and Classification

Retinal migraine is defined as repeated attacks of monocular visual disturbance, including scintillations, scotomata, or blindness, associated with headache, with all symptoms being fully reversible. This condition specifically involves transient impairment in in one eye, distinguishing it from more common binocular visual auras in . In the classification system of the (IHS), retinal migraine is categorized under with in the 3rd edition of the (ICHD-3, 2018), assigned the code 1.2.4. This placement emphasizes its status as a subtype of with , requiring fulfillment of general criteria alongside monocular specificity to differentiate it from typical visual affecting both eyes. The diagnostic criteria for retinal migraine per ICHD-3 include at least two attacks meeting the standards for migraine with aura, featuring fully reversible positive and/or negative visual phenomena (such as flickering lights, spots, lines, or partial/complete vision loss), confirmed by clinical examination or patient-drawn field defects during an attack. These attacks must not be better explained by another ICHD-3 diagnosis, underscoring retinal migraine as a after ruling out other causes of transient loss. There remains debate in the regarding whether migraine constitutes a truly distinct clinical entity or merely a variant of standard with , with some experts questioning the term due to potential differences in underlying mechanisms between cortical and processes. This has evolved across ICHD editions since 1988, refining criteria to address historical inconsistencies in terminology and inclusion standards.

Epidemiology

Retinal migraine is a rare subtype of , estimated to occur in approximately 1 in 200 individuals who suffer from . This is substantially lower than that of migraine with , which affects about 25-30% of all migraineurs. Specific population-level data for retinal migraine remain limited due to diagnostic challenges and underreporting, with only around 12 well-documented cases meeting strict criteria between 2006 and 2020. The condition predominantly affects females, with a female-to-male ratio ranging from 2:1 to 2.5:1. Onset typically occurs in the 20s to 40s, with a mean age around 25 to 39 years, though cases have been reported as early as age 7 in children and up to the fifth decade in older adults. Approximately 29% of individuals with retinal migraine have a personal history of , and up to 50% report a family history, suggesting a genetic component. Incidence data are scarce, but a 2022 review estimates annual incidence in the general population at less than 0.01%, rising to higher rates among those with a personal or family history of , where with classic migraine reaches up to 29%. Limited evidence indicates no strong geographic or ethnic variations, though underdiagnosis may occur in non-Western populations due to limited access to specialized neurological care.

Clinical Features

Visual Symptoms

Retinal migraine primarily manifests as transient visual loss, typically in the form of a that ranges from partial field defects to complete blindness in one eye. This disturbance is fully reversible and occurs without permanent sequelae in uncomplicated cases. The affected eye experiences unilateral involvement, distinguishing it from binocular visual auras in typical , and in recurrent episodes, the involvement may alternate between eyes. Additional visual phenomena include , (flashing lights), zigzag patterns, , or colored spots and lines, which often originate in the central and gradually spread outward. These symptoms develop suddenly and progressively intensify during the episode. Complete vision loss is less common, reported in approximately 8% of cases according to a 2025 . The duration of these visual symptoms is characteristically brief, lasting from 5 to , with most episodes resolving within 10 to 20 minutes. Attacks occur infrequently, often 1 to 2 times per month, though the exact varies among individuals. These ocular disturbances typically precede the phase, often serving as the initial indicator of an impending attack.

Headache and Other Symptoms

In retinal migraine, the headache phase typically manifests as unilateral, throbbing pain that is often ipsilateral to the visual disturbance, with moderate to severe intensity. This pain is usually pulsating or pounding, frequently localized behind the affected eye, and may worsen with physical activity such as walking or climbing stairs. If untreated, the headache can persist for 4 to 72 hours, aligning with the duration criteria for migraine attacks in the International Classification of Headache Disorders (ICHD-3). Associated symptoms during the headache phase mirror those of classic migraine and include , , , , and osmophobia. Additional accompaniments may involve loss of appetite, sweating or , , and tiredness, contributing to overall discomfort. The visual aura in retinal migraine typically resolves before or during the onset of in approximately 70-75% of cases, with the headache commencing within 60 minutes of aura symptoms. In about 25% of attacks, however, no headache occurs, classifying these as episodes. The full attack, encompassing both visual and headache phases, generally resolves within hours, though the headache may linger longer if unaddressed. Auras without accompanying headache are more prevalent in older adults. Prodromal or postdromal phases occur in approximately 60-70% of general episodes and may also feature in retinal migraine, though specific prevalence is unknown due to rarity. These phases provide subtle indicators of impending or resolving symptoms.

Pathophysiology

Underlying Mechanisms

The primary mechanism underlying retinal migraine involves retinal , which leads to transient ischemia in the retinal circulation and results in monocular visual loss. This is thought to cause a temporary reduction in blood flow to the , producing symptoms such as or complete visual obscuration in the affected eye, typically lasting 5 to 60 minutes. Unlike typical migraine aura, which affects both visual fields, the unilateral nature of retinal migraine symptoms points to involvement of the retinal vasculature rather than cortical processing alone. Cortical spreading depression (CSD) plays a role in more broadly, manifesting as a wave of neuronal across the occipital cortex that triggers trigeminovascular activation and subsequent . In retinal migraine, retinal effects may arise from involvement or direct spasm of the retinal artery, potentially extending -like phenomena to the itself. This process is hypothesized to contribute to the visual disturbances by disrupting retinal neuronal activity, though direct evidence in the retina remains limited compared to cortical aura mechanisms. Neurogenic inflammation further contributes to the vascular instability in retinal migraine through the release of neuropeptides such as (CGRP) and from endings. These mediators promote cycles of vessel constriction and dilation, exacerbating ischemia and pain signaling in the retinal and ophthalmic circulations. The involvement of CGRP in particular underscores a shared pathway with other subtypes, where perivascular release leads to and inflammatory responses. Imaging evidence supports these mechanisms, with fundus fluorescein angiography demonstrating delayed retinal arterial filling during acute attacks, indicative of and ischemia. (OCT) studies have shown subtle thinning in migraine patients, potentially indicating cumulative ischemic effects, though transient changes during retinal migraine attacks are not well-documented. Recent research from 2022 to 2025 highlights the role of , showing that CGRP antagonists, such as monoclonal antibodies, reduce attack frequency in patients, including those with retinal involvement, thereby supporting the inflammatory component of the . These therapies also stabilize retinal and changes, potentially offering against repeated ischemic events. Unlike , which is linked to specific mutations, no unique genetic mutations have been identified for retinal migraine, though a familial predisposition exists without a clear pattern.

Risk Factors

Retinal migraine susceptibility is influenced by both non-modifiable and modifiable risk factors, similar to other disorders. Non-modifiable factors include a family history of , which is reported in approximately 30-50% of cases and confers an increased of about 3-4 for developing subtypes, including retinal migraine. sex is also a key non-modifiable , with studies showing a predominance of cases in women (61-83% across cohorts). The typical age of onset falls between 20 and 40 years, peaking in the third and fourth decades. Modifiable risk factors play a significant role in exacerbating susceptibility. increases the risk of , a proposed in retinal migraine, with odds ratios indicating at least a twofold elevation in related vascular events. Oral contraceptive use in women heightens risk due to hormonal influences on vascular reactivity. High intake and are additional modifiable contributors, as both can precipitate attacks by affecting cerebral blood flow. Sleep disturbances further compound vulnerability by disrupting migraine thresholds. Certain comorbidities amplify the risk of retinal migraine through enhanced vascular reactivity. Conditions such as and are associated with higher incidence, as they promote that may interact with pathways. Autoimmune disorders, including , also elevate susceptibility by contributing to and . Notably, about 29% of individuals with retinal migraine have a prior history of classic , indicating substantial overlap. Specific triggers for retinal migraine often differ from those of binocular visual auras in migraine with aura, focusing more on monocular vascular perturbations. These include exposure to bright lights, which can provoke retinal ischemia in susceptible individuals; hormonal fluctuations, particularly in women; and , which reduces ocular . Recent studies up to 2025 have found no strong causal link between COVID-19 vaccination and retinal migraine onset, though post-viral inflammatory states may unmask latent predispositions in at-risk individuals.

Diagnosis

Clinical Evaluation

The clinical evaluation of retinal migraine begins with a thorough history taking to characterize the attacks. Patients typically describe transient visual disturbances, such as , scintillations, or blindness, lasting 5 to 60 minutes, which are fully reversible. The nature is confirmed through report or subsequent examination, distinguishing it from binocular visual auras in typical . These episodes are often followed within 60 minutes by a , typically ipsilateral, though the headache may be absent in some instances. A family history of is reported in approximately 50% of patients, and common triggers include stress, smoking, , hormonal contraceptives, and . Physical examination focuses on ruling out underlying during or shortly after an attack. Fundoscopic examination may reveal transient retinal or hypoperfusion, though findings are often normal interictally. A comprehensive is performed to assess for focal deficits, which are typically absent except for the monocular visual impairment. Initial diagnostic tests emphasize ocular assessment to confirm the deficit and exclude other causes. Visual acuity testing identifies any temporary reduction in the affected eye, while testing, such as Humphrey perimetry, demonstrates the monocular field defect and aids in verifying the characteristics. measurement is conducted to rule out acute or other intraocular abnormalities. Neuroimaging and vascular studies are recommended in select cases to exclude serious mimics. MRI or is indicated if the presentation is atypical, such as prolonged symptoms or neurological signs, to rule out or structural lesions. is advised for first-time episodes or in older patients to assess for vascular or embolic sources. Diagnosis is confirmed by applying the , 3rd edition (ICHD-3) criteria, requiring at least two attacks of fully reversible visual phenomena—positive (e.g., scintillations) or negative (e.g., )—lasting 5 to 60 minutes, with gradual development over at least 5 minutes, accompanied, or followed within 60 minutes, by typical ; or, if not, accompanied by typical (other than the visual phenomena) or typical , and normal interictal neuro-ophthalmic examinations. The must be verified by clinical testing or patient-drawn field defect during an attack.

Differential Diagnosis

Retinal migraine is a , necessitating the ruling out of other serious causes of transient monocular visual loss (TMVL) through clinical evaluation and targeted investigations. Vascular conditions that mimic retinal migraine include , typically resulting from (TIA) or emboli originating from carotid or cardiac sources, which presents with abrupt, brief episodes of vision loss often described as a curtain descending over the . Central or branch retinal artery occlusion causes more prolonged or irreversible monocular vision impairment due to ischemic damage, distinguishing it from the fully reversible symptoms in retinal migraine. (GCA) may simulate retinal migraine with monocular visual disturbances accompanied by temporal , scalp tenderness, jaw claudication, and elevated (ESR), requiring prompt therapy to prevent complications like permanent blindness. Ocular disorders to consider include , which typically manifests with persistent , floaters, and a progressive veil-like shadow across the vision, lacking the rapid resolution seen in retinal migraine. Vitreous hemorrhage leads to sudden, painless, non-reversible blurring or loss of vision due to blood accumulation in the vitreous, often linked to underlying retinal vascular issues. , frequently associated with , presents with subacute monocular vision loss exacerbated by eye movement and accompanied by pain, potentially bilateral or recurrent but not typically resolving within an hour. Neurological mimics encompass TIA beyond vascular origins, which can produce sudden or hemianopic deficits without accompanying or migrainous features like . Partial seizures, such as those originating in the , may cause brief visual hallucinations or scotomas but often occur without , , or the stereotypical progression of migrainous auras. Multiple sclerosis-related can mimic recurrent episodes but is characterized by persistent or demyelination-linked symptoms, potentially with other focal neurological signs like limb weakness. Key differentiators of retinal migraine include its , reversible visual disturbances—often featuring positive scintillating scotomas lasting 5 to 60 minutes—followed by ipsilateral headache within one hour, with a history of recurrent migraines in affected individuals, in contrast to the permanent retinal damage or non-migrainous patterns in occlusive or inflammatory conditions. Red flags prompting urgent evaluation include sudden-onset TMVL in individuals over 50 years, bilateral visual involvement, symptoms persisting beyond , or concomitant neurological deficits such as weakness or altered consciousness, which necessitate immediate to exclude TIA, , or GCA. Recent reports have highlighted increased recognition of post-vaccination TMVL following immunization, such as multiple transient monocular episodes in otherwise healthy adults shortly after Pfizer-BioNTech vaccination, which can closely resemble retinal migraine and require exclusion of embolic or vasospastic etiologies.

Management

Acute Treatment

The acute treatment of retinal migraine focuses on providing symptomatic relief during an attack, particularly for associated and visual disturbances, while avoiding therapies that may exacerbate . First-line interventions typically involve over-the-counter oral analgesics taken at the onset of symptoms. Ibuprofen at doses of 400-600 mg or acetaminophen at 1 g is recommended for mild to moderate pain, as these nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics can reduce and discomfort without significant vascular risks. Non-pharmacologic measures are essential for immediate relief and include resting in a dark, quiet room to minimize sensory triggers, applying cold compresses to the forehead or neck to potentially alleviate and intensity, and ensuring adequate to support overall vascular stability. These approaches are simple, accessible, and can shorten attack duration when combined with analgesics. If dry eye symptoms accompany visual disturbances, ocular lubricants may provide additional comfort by reducing irritation. Vasodilators such as should be strictly avoided, as they could worsen retinal . For severe attacks with prominent or , escalation may involve antiemetics like metoclopramide to manage gastrointestinal symptoms, alongside higher-dose NSAIDs if initial therapy fails. , such as (50-100 mg oral or subcutaneous) or (), are contraindicated due to the risk of prolonging or worsening visual loss from , particularly in patients with vascular concerns. In general populations, achieve approximately 70% relief at two hours, though evidence specific to the retinal subtype remains limited owing to its rarity.

Preventive Strategies

Preventive strategies for retinal migraine are indicated for frequent attacks (more than one per month), significant impairment to daily activities or , or even infrequent episodes to prevent potential permanent vision loss. These measures aim to reduce the frequency and severity of visual auras and associated headaches by targeting vascular and neurological components of the condition. First-line pharmacological options include , which are preferred due to their vasodilatory effects that may mitigate retinal . Verapamil, at doses of 240-480 mg per day divided into three or four administrations, has shown in reducing attack frequency in prophylaxis, including cases with . is another option, though evidence is more limited. Beta-blockers such as (40-240 mg/day) are generally avoided in retinal due to the potential risk of exacerbating and causing irreversible vision loss. Anticonvulsants like topiramate (50-200 mg/day) or are used for prevention with caution due to potential ocular side effects, such as ; topiramate demonstrating a 50% reduction in monthly days in clinical trials for episodic . Low-dose aspirin may also be considered for prevention to improve blood flow. Emerging therapies include (CGRP) monoclonal antibodies, such as (70-140 mg monthly subcutaneous injection), which have shown promise in trials for (as of 2025) by reducing burden and stabilizing retinal structural changes in general patients, though evidence specific to retinal is limited. Lifestyle modifications play a crucial role in prevention by addressing common triggers. Patients should avoid factors such as , excessive , , and uncontrolled , while maintaining regular patterns to minimize episode provocation. techniques, including and (CBT), can reduce attack frequency by up to 50% in migraine cohorts. Dietary adjustments, such as magnesium supplementation at 400 mg per day, support neuronal stability and have been associated with fewer migraine days in preventive studies. Evidence from small cohorts indicates that achieve a 50-60% reduction in attack frequency, though larger trials specific to retinal migraine are lacking. Recent research, including 2025 studies on CGRP inhibitors, supports their use in cases with improvements in both frequency and retinal health metrics. Patients on preventive should maintain a diary to track efficacy and undergo regular ophthalmologic follow-up to monitor retinal health and detect any complications early.

Prognosis

Long-Term Outcomes

Retinal migraine is generally regarded as a benign condition, with visual disturbances typically fully reversible within minutes to an hour, resulting in no permanent visual deficits in the vast majority of cases. Permanent visual loss, while possible due to prolonged retinal ischemia, remains uncommon and is not a typical outcome. The frequency and severity of attacks often diminish over time, particularly as patients age, contributing to an overall favorable long-term trajectory. Remission patterns for retinal migraine are thought to mirror those of migraine with aura more broadly, though specific data is limited due to the condition's rarity. For general migraine with aura, spontaneous resolution is reported in approximately 20-30% of cases by age 50, with higher rates among men compared to women. However, the condition may persist longer in individuals with comorbid typical migraine headaches, potentially leading to recurrent episodes into later adulthood. Limited specific data exists due to the rarity of retinal migraine, but general trends suggest a natural decline in attack frequency for many patients. The impact on quality of life is primarily episodic, with temporary causing during attacks, such as inability to drive or perform visual tasks, yet overall morbidity remains low given the transient nature of symptoms. Progression to is rare, and most individuals experience minimal long-term interference with daily functioning. Longitudinal follow-up data, including studies spanning up to 20 years, indicate that the stroke risk associated with retinal migraine aligns with that of the broader with population, showing approximately a twofold increase compared to non-migraineurs but no excess beyond this subgroup. Early preventive measures can enhance outcomes particularly in high-risk groups such as younger women or those with vascular comorbidities.

Complications and Monitoring

Retinal migraine is generally benign, but rare complications can arise, particularly in untreated or recurrent cases. Permanent vision loss is rare, often due to repeated leading to retinal ischemia or , or from prolonged . Such outcomes are documented in case reports of migrainous affecting the retina or , emphasizing the need for prompt to prevent irreversible damage. Recent as of 2024 has identified an increased risk of retinal vascular occlusion in patients with migraine, which may contribute to long-term complications. Patients with retinal migraine face a slightly elevated of ischemic events, with odds ratios of 1.5 to 2.0 for , attributed to shared vascular mechanisms with transient ischemic attacks (TIAs). This is particularly relevant in individuals over 40 years or those with additional cardiovascular factors, such as or , warranting vigilant surveillance. Monitoring protocols for retinal migraine include annual ophthalmologic examinations featuring funduscopy to assess retinal health and (OCT) to detect subtle changes in thickness or microvascular alterations. control and lipid screening are recommended as part of routine cardiovascular assessment, with advised if attack patterns change, such as increased frequency or atypical symptoms, to rule out evolving vascular . Patient education is crucial, focusing on recognition of like persistent vision loss beyond typical attack duration or new neurological symptoms, which necessitate immediate evaluation to exclude or other serious conditions. Recent 2024 confirms no evidence of increased risk in patients with , including retinal variants, based on case-control studies showing no significant association after adjusting for confounders. However, emphasis is placed on to mitigate vascular complications, as use exacerbates risk in migraineurs beyond baseline levels.

References

  1. [1]
    Retinal Migraine Headache - StatPearls - NCBI Bookshelf - NIH
    Ocular or retinal migraines are generally defined as a transient monocular scotoma or loss of vision that is accompanied or followed by a headache within 60 ...Missing: credible | Show results with:credible
  2. [2]
    Retinal Migraine: Symptoms, Causes and Treatment | AMF
    May 12, 2022 · Retinal migraine is a rare type of migraine that causes visual disturbances in one eye. Learn the symptoms to seek proper treatment.Missing: credible sources
  3. [3]
    Ocular Migraine: What It Is, Causes, Symptoms & Treatment
    Ocular migraine (retinal migraine) involves attacks of visual issues that affect one eye and migraine headaches. The visual disturbances are temporary.Missing: credible | Show results with:credible
  4. [4]
    Current Perspective on Retinal Migraine - PMC - PubMed Central
    Aug 23, 2021 · The 1988 ICHD defined retinal migraine as 'at least two attacks' of fully reversible monocular visual disturbance with typical migraine headache ...Missing: credible | Show results with:credible
  5. [5]
    Retinal migraine - NHS
    Retinal migraines are a type of migraine that affect the eyes. They can cause temporary vision loss in 1 eye and other eye symptoms.Missing: definition credible
  6. [6]
    None
    Nothing is retrieved...<|control11|><|separator|>
  7. [7]
    [PDF] International Classification of Headache Disorders, 3rd edition
    The 3rd edition of the International Classification of. Headache Disorders (ICHD-3) may be reproduced freely for scientific, educational or clinical uses by ...
  8. [8]
    Current Perspective on Retinal Migraine - MDPI
    In contrast with migraine with visual aura, most retinal migraine cases reported to date present with negative symptoms (such as visual field defects including ...
  9. [9]
    [PDF] Basilar Migraines and Retinal Migraines
    Retinal migraine is rare; strictly monocular visual phe- nomena occur in only 1 in 200 migraine sufferers (27). Epidemiologic studies of retinal migraine ...
  10. [10]
    Migraine Headache - Medscape Reference
    Aug 26, 2024 · The female-to-male ratio increases from 2.5:1 at puberty to 3.5:1 at age 40 years.<|separator|>
  11. [11]
    [PDF] Retinal migraine, a contentious clinical entity
    Sep 28, 2022 · Even though based on the statistics, retinal migraine tends to affect women more so than men [6] and begins in the second to third decades, with ...
  12. [12]
    Retinal migraine - MedLink Neurology
    Retinal migraine is most common in women of childbearing age who have a history of migraine with aura. In the typical attack, monocular visual features consist ...
  13. [13]
    What does a migraine aura look like?—A systematic review
    Jul 1, 2025 · Visual symptoms that meet ICHD-3 criteria for retinal migraine are incredibly rare, and previous reviews have only identified a limited number ...<|separator|>
  14. [14]
    Retinal migraine - PubMed
    Retinal migraine is usually characterized by attacks of fully reversible monocular visual loss associated with migraine headache.
  15. [15]
    Migraine variants: Nursing considerations - Nursing2025
    ... retinal migraine, and abdominal migraine. The authors discuss the ... In one study, 50% of patients with RM reported complete vision loss in one ...Hemiplegic Migraine · Managing Rm · Managing Am
  16. [16]
    Retinal migraine: Causes, symptoms, and treatment
    Retinal migraines, or ocular migraines, involve visual disturbances such as flashing lights or vision loss in one eye, often followed by a headache.Missing: definition | Show results with:definition
  17. [17]
    https://www.medicalnewstoday.com/articles/314917
  18. [18]
    Characterizing Prodrome (Premonitory Phase) in Migraine
    Oct 8, 2024 · The most common prodromal symptoms identified were sensitivity to light (57.2%; 2,748/4,802), fatigue (50.1%; 2,408/4,802), neck pain (41.9%; ...
  19. [19]
    Pre- and post-headache phases of migraine: multi-country results ...
    Nov 8, 2023 · The prodrome phase is characterized by symptoms that may begin hours to days before the headache and may include neck stiffness, fatigue, ...
  20. [20]
    Migraine Associated With Monocular Visual Symptoms (CME) - Evans
    Dec 20, 2007 · The underlying pathophysiology of retinal migraine remains largely unknown. In some cases, vasospasm of the retinal or ciliary circulation may ...
  21. [21]
    Ophthalmologic Manifestations of Migraines - EyeWiki
    ... or temporary blindness, often accompanied by migraine headaches. Migraine with binocular blindness that presents with characteristic migraine features ...
  22. [22]
    Involvement of CGRP receptors in retinal spreading depression
    Cortical spreading depression (CSD) is a transient propagating excitation of synaptic activity followed by depression, which is implicated in migraine with aura ...
  23. [23]
    Understanding migraine: Potential role of neurogenic inflammation
    Neurogenic inflammation, a well-defined pathophysiologial process is characterized by the release of potent vasoactive neuropeptides, predominantly calcitonin ...Missing: retinal | Show results with:retinal
  24. [24]
    Calcitonin gene-related peptide in migraine - PubMed Central - NIH
    Perivascular release of CGRP from the trigeminal nerve induces vasodilation and dural mast cell degranulation, which both contribute to neurogenic inflammation.
  25. [25]
    Calcitonin Gene-Related Peptide (CGRP) Antibodies in ... - EyeWiki
    Jul 14, 2025 · CGRP contributes to neurogenic inflammation by activating the release of neurokinin A and substance P, which leads to plasma extravasation ...
  26. [26]
    Using optical coherence tomography and ... - PubMed Central - NIH
    They showed that migraineurs had reduced retinal thickness (via OCT), retinal vessel density, and greater foveal avascular zone area (via OCTA) than controls.Retina · Optic Nerve · Choroid
  27. [27]
    Anti-CGRP Therapy Reduces Migraines, Improves Retinal Findings
    Jul 28, 2025 · Anti-CGRP monoclonal antibody therapy in patients with migraine can reduce headache burden and stabilize retinal and optic nerve changes.Missing: antagonists 2022-2025
  28. [28]
    Evaluating the impact of anti-CGRP monoclonal antibodies on ...
    Jun 24, 2025 · Short-term treatment with anti-CGRP mAbs may exert neuroprotective effects, potentially preventing permanent ocular damage.
  29. [29]
    Familial Retinal Migraines - PubMed
    Two families with retinal migraines are reported suggesting an autosomal-dominant inheritance pattern with variable expression and penetrance.Missing: mutations | Show results with:mutations
  30. [30]
    Family History of Migraine Associated With Posttraumatic ... - PubMed
    Results: Patients with a family history of migraine were 2.6 times (odds ratio = 2.60, confidence interval = 1.35-5.02, P = .003) more likely to present ...
  31. [31]
    Smoking is a risk factor for coronary spasm in young women.
    The odds ratio of cigarette smoking and coronary spasm was. 7.7, with a 95% confidence interval of 2.6-23.1. No study participant had ever smoked cigars ...
  32. [32]
    Why Am I Getting Ocular Migraines? - DMEI
    May 1, 2024 · ... migraine triggers. Exposure to bright lights: For people sensitive to light, exposure to bright natural or artificial light can be a trigger.
  33. [33]
    New insights into the increased risk of migraines from COVID-19 ...
    Oct 24, 2024 · This study provides novel evidence of a significant causal link between COVID-19 vaccination and migraine, while no such association was observed with COVID-19 ...Missing: retinal | Show results with:retinal
  34. [34]
    Link Between Ocular Migraine And Covid - HealthMatch
    Some people have complained of ocular migraine after getting the COVID-19 vaccine ... For some people, migraine with aura can increase the risk of stroke.
  35. [35]
    Multiple attacks of transient monocular visual loss in a previously ...
    Jun 20, 2022 · We report a case of multiple attacks of transient monocular visual loss in a previously healthy middle-aged man two weeks after Pfizer-BioNTech COVID-19 ...Missing: post-
  36. [36]
    What Ophthalmologists Need to Know About Migraine
    Sep 1, 2022 · Symptoms of ocular surface disease are more common among individuals with migraine than among those who don't get migraines, according to Dr.<|separator|>
  37. [37]
    Retinal Migraine: Symptoms, Causes and Treatments - Neura Health
    Aug 25, 2022 · If episodes are infrequent, non-steroidal anti-inflammatory medications (NSAIDs) are often prescribed for pain relief. Triptans and ergotamines ...
  38. [38]
    Ocular Migraine - What You Need to Know - Drugs.com
    Use an ice pack, or put crushed ice in a plastic bag. Cover the ice pack with a towel and place it on your head. Apply ice for 15 to 20 minutes every hour, or ...
  39. [39]
    How to Get Rid of an Ocular Migraine - Complete Eye Care of Medina
    Use a Cold Compress. Placing a cold compress on your forehead or the back of your neck can help assuage the severity of the headache. You can use a ...
  40. [40]
    Maximum Effect of Triptans in Migraine? A Comment - Sage Journals
    For oral triptans the maximum response for headache relief is approximately 70% when treating moderate or severe headache with rizatriptan 10 mg or eletriptan ...
  41. [41]
    Verapamil in migraine prophylaxis--a five-year review - PubMed
    Verapamil is a papaverine derivative calcium channel blocking drug that has been effectively utilized in the prophylaxis of migraine.Missing: beta | Show results with:beta
  42. [42]
    Topiramate in Migraine Prevention: Results of a Large Controlled Trial
    Conclusion Topiramate, 100 or 200 mg/d, was effective as a preventive therapy for patients with migraine.Missing: retinal | Show results with:retinal
  43. [43]
    Magnesium and Migraine | American Migraine Foundation
    Oct 20, 2021 · Magnesium oxide is frequently used in pill form to prevent migraine, usually at a dose of 400-600 mg per day.
  44. [44]
    Retinal migraine - PMC - PubMed Central - NIH
    Retinal migraine is an ophthalmo-pathological condition described as a transient monocular scotoma or vision loss, being accompanied or followed by a headache.Pathophysiological Effectors... · Fig. 1 · Fig. 2Missing: fundoscopic acuity<|control11|><|separator|>
  45. [45]
    Retinal migraine - ScienceDirect.com
    Retinal migraine is thought to be a rare disorder, but its true prevalence and incidence are unknown. In a review of the literature, Hill et al. (2007) applied ...
  46. [46]
    [PDF] Prognosis of Migraines
    Jul 25, 2005 · In men the persistence rate was 48% and in women. 79%, suggesting a higher rate of remission in young adult- hood among men compared with women ...
  47. [47]
    Patients With Migraine Have Substantial Reductions in Measures of ...
    Jun 7, 2018 · Conclusions: Visual quality of life is significantly adversely affected in migraine sufferers. In fact, patients with chronic migraine may have ...Missing: retinal | Show results with:retinal
  48. [48]
    Ischemic stroke subtypes and migraine with visual aura in the ARIC ...
    Migraine with visual aura was linked to increased stroke risk, while migraine without visual aura was not, over the period of 20 years. These results are ...Missing: prognosis remission
  49. [49]
    Migraine and risk of stroke
    Numerous studies, including five meta-analyses,4–8 have linked migraine, particularly migraine with aura (MA), with increased risk of ischaemic stroke (table 1) ...Missing: prognosis | Show results with:prognosis
  50. [50]
    Migraine and stroke: correlation, coexistence, dependence
    Feb 20, 2025 · Migraine is linked to worse outcomes after ischemic stroke, including larger stroke volumes and poorer functional outcomes.Missing: indications | Show results with:indications
  51. [51]
    Migrainous infarction of the eye: Two cases of monocular ischemic ...
    Nov 17, 2021 · Retinal migraine can complicate with permanent monocular visual loss, suggesting potential migrainous infarction of the retina or optic nerve.
  52. [52]
    The Migraine Association with Cardiac Anomalies, Cardiovascular ...
    The Stroke Prevention in Young Women Study found that women aged 15–49 with probable migraine with aura had an odds ratio of 1.5 (95% CI 1.1–2.0) for ischemic ...Missing: retinal | Show results with:retinal
  53. [53]
    Migraine and risk of stroke - PMC - PubMed Central
    Migraine patients with aura should be advised to stop smoking, particularly if they also take oral contraceptives. Oral contraceptive use should be carefully ...<|control11|><|separator|>
  54. [54]
    Ocular migraine: When to seek help - Mayo Clinic
    Retinal migraine · Visual changes in only one eye. · Visual changes that last less than five minutes or more than 60 minutes. · Visual changes without a headache.
  55. [55]
    Migraine headache and other risk factors associated with glaucoma ...
    Apr 22, 2024 · Purpose: This study aimed to assess the association between migraine headache and glaucoma among the adult population living in Armenia.Missing: research retinal
  56. [56]
    The Relationship of Tobacco Use and Migraine: A Narrative Review
    Mar 11, 2023 · Migraine and Smoking Cessation​​ Little is known about characteristics of smoking that increase difficulty of quitting among people with migraine ...Missing: complications | Show results with:complications